Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
AJ Scheen - Expert Opinion on Drug Safety, 2024 - Taylor & Francis
Introduction Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities
Diabetes mellitus is a significant risk factor for both ischaemic and haemorrhagic stroke,
affecting up to a third of individuals with cerebrovascular diseases. Beyond being a risk …
affecting up to a third of individuals with cerebrovascular diseases. Beyond being a risk …
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review
AJ Scheen - Diabetes & Metabolism, 2023 - Elsevier
Abstract Background.-Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-
glucose cotransporter 2 inhibitors (SGLT2is), while developed as antihyperglycaemic …
glucose cotransporter 2 inhibitors (SGLT2is), while developed as antihyperglycaemic …
[HTML][HTML] Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease: Underuse of GLP-1RAs in …
AJ Scheen - Diabetes Epidemiology and Management, 2024 - Elsevier
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce the risk of
cardiovascular (CV) complications in patients with type 2 diabetes (T2DM) and …
cardiovascular (CV) complications in patients with type 2 diabetes (T2DM) and …
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
IH Vieira, TS Carvalho, J Saraiva, L Gomes, I Paiva - Biomedicines, 2024 - mdpi.com
Type 2 diabetes mellitus (T2DM) is a significant risk factor for stroke. Nevertheless, the
evidence supporting stringent glycemic control to reduce macrovascular complications …
evidence supporting stringent glycemic control to reduce macrovascular complications …
Type 2 diabetes mellitus in patients with ischemic stroke–A nationwide study
S Hastrup, JN Hedegaard, G Andersen… - Diabetic …, 2024 - Wiley Online Library
Abstract Aims Type 2 diabetes (T2D) is a risk factor for ischemic stroke (IS) and associated
with an adverse prognosis. Both stroke and diabetes care has evolved substantially during …
with an adverse prognosis. Both stroke and diabetes care has evolved substantially during …
[HTML][HTML] Similar incidence of stroke with SGLT2 inhibitors and GLP-1 receptor agonists in real-world cohort studies among patients with type 2 diabetes: SGLT2is vs …
AJ Scheen - Diabetes Epidemiology and Management, 2023 - Elsevier
Background Stroke represents a major burden in patients with type 2 diabetes. Yet, this
cerebrovascular complication has been less well studied than coronary artery disease and …
cerebrovascular complication has been less well studied than coronary artery disease and …